Title
Clinical onset of atopic eczema: Results from two nationally representative British birth cohorts followed through mid-life.

Permalink
https://escholarship.org/uc/item/5bs2d36p

Authors
Abuabara, Katrina
Ye, Morgan
McCulloch, Charles E
et al.

Publication Date
2019-06-28

DOI
10.1016/j.jaci.2019.05.040

Peer reviewed
Title: Clinical onset of atopic eczema: Results from two nationally representative British birth cohorts followed through mid-life

Katrina Abuabara, MD, MA, MSCE
Morgan Ye, MPH
Charles E McCulloch, PhD
Alice Sullivan, PhD
David J. Margolis, MD, PhD
David P. Strachan, MD
Lavinia Paternoster, PhD
Yik Weng Yew, MD, MPH
Hywel C. Williams, FRCP, DSc
Sinéad M. Langan, FRCP, PhD

1. Program for Clinical Research, Department of Dermatology, University of California, San Francisco School of Medicine (UCSF), San Francisco, CA, USA
2. Division of Biostatistics, University of California, San Francisco School of Medicine (UCSF), San Francisco, CA, USA
3. UCL Institute of Education, University College London, UK
4. Department of Dermatology and Center for Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
5. Population Health Research Institute, St George’s University of London, London, UK
6. MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK
7. National Skin Centre, Singapore
8. Centre of Evidence Based Dermatology, Faculty of Medicine & Health Sciences, University of Nottingham
9. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK

Correspondence to:
Katrina Abuabara
University of California San Francisco (UCSF)
2341 Sutter Street, N421, San Francisco, CA 94115
Email: Katrina.abuabara@ucsf.edu
Office phone: 415-502-0433

Word Count: 3,388
Tables/Figures: 3 Tables, 3 Figures
Supplement: Supplementary Methods, 7 Tables, 1 Figure

Funding and competing interests statement: KA is supported by grants from the Robert Wood Johnson Foundation, and the NIH (K23AR073915). SML
is supported by a Wellcome Senior Clinical fellowship in Science (205039/Z/16/Z). DJM receives funding to the University of Pennsylvania from NIH and Valeant for studies not directly related to this manuscript. He receives consulting funds from Leo, Sanofi, and Pfizer for topics related to AD but not this manuscript. KA is a consultant to TARGET, a company developing an atopic dermatitis registry.

We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. Genotyping for the B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC genotyping utilized resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research (CIMR), University of Cambridge, which is funded by Juvenile Diabetes Research Foundation International, the Wellcome Trust and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). The B58C-GABRIEL genotyping was supported by a contract from the European Commission Framework Programme 6 (018996) and grants from the French Ministry of Research. FLG genotyping was funded by an MRC centenary award (awarded to L Paternoster)

The funding agencies did not have any influence on design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.
Abstract (224/250 words)

Background: Atopic eczema onset is described primarily in early childhood; the frequency and characteristics of adult-onset disease remain controversial.

Objective: To determine the proportion of individuals who report atopic eczema symptoms between birth and mid adulthood, and to examine demographic, immunologic, and genetic factors associated with period of symptom onset.

Methods: We conducted a longitudinal study using data from two nationally representative community-based birth cohorts from the United Kingdom: the British Cohort Studies 1958 and 1970. Individuals were followed from birth through age 42-50. The primary outcome was the age period of self-reported atopic eczema symptom onset based on repeated measures of self-reported atopic eczema at each survey wave.

Results: The annual period prevalence of atopic eczema ranged from 5-15% in two cohorts of over 17,000 participants each followed from birth through mid-age. There was no clear trend in prevalence by age, and among adults reporting active atopic eczema during a given year, only 38% had symptom onset reported in childhood. When compared with individuals whose eczema started in childhood, those with adult-onset disease were more likely to be women, from Scotland or Northern England, of lower childhood socio-economic group, smokers in adulthood, and less likely to have a history of asthma. In a sub-analysis using data from the 1958 cohort only, genetic mutations previously associated with atopic eczema, including filaggrin null mutations, and allergen-specific IgE were more common among those with childhood-onset disease.

Conclusion: Rates of self-reported atopic eczema remain high after childhood, and adult-onset atopic eczema has different risk factor associations than childhood-onset eczema.

Clinical Implication: Adult-onset eczema is common and may be less likely to present with other atopic disease.
Capsule Summary (29/30 words): In two nationally representative birth cohorts followed through mid-life, adult-onset eczema was most common, and the strength of association with demographic, immunologic and genetic factors differed from childhood-onset disease.

Key words: atopic eczema, atopic dermatitis, natural history, epidemiology

Abbreviations:
BCS: British Cohort Study
CI: Confidence interval
OR: Odds Ratio
UK: United Kingdom
Introduction

Atopic eczema (also known as atopic dermatitis or just eczema) is the leading cause of skin-related disability,(1) but most epidemiological research has focused only on incidence early in life or patterns of disease in childhood.(2) Recent data suggest that atopic eczema is also common among adults, but whether these trends are due to increasing persistence of disease or new-onset disease later in life is unclear.(3-5) Atopic eczema is known to wax and wane over time, yet there are limited longitudinal data on patterns of disease activity over the life course. Cross-sectional studies have reported proportions of adult-onset atopic eczema ranging from 13-60%.(6-15) The validity of these estimates have been questioned because of the potential for recall bias (adults may not accurately recall whether they had eczema as children) or the possibility that disease expression in adulthood is due to migration from low to high prevalence climates.(16) In addition, studies of dermatology clinic populations suggest that there may be important genetic and phenotypic differences in adult-onset disease, but these may not be representative of the general population and are controversial for the reasons stated above. Data from population-based longitudinal birth cohorts are needed to understand the patterns and predictors of atopic eczema presentation across the life course.

It is important to understand the epidemiology of adult-onset atopic eczema for a number of reasons. First, since most diagnostic criteria specify that disease begins early in childhood, patients and providers may feel uncertain of the diagnosis in adults with new onset disease. While additional testing is often appropriate to rule out differential diagnoses,(17) if many adults don’t meet the diagnostic criteria developed for children, they may be subject to anxiety about the lack of a clear diagnosis, excessive testing, and limited access to new treatment options.(18) Second, if risk factors for adult-onset atopic eczema differ, this raises the possibility of a different subtype of atopic eczema and could help to elucidate differences in disease pathophysiology and drivers of disease activity. Finally, understanding if childhood-onset and adult-onset atopic eczema differ is important for refining preventative and treatment strategies. The latter is particularly timely because many new small molecules and biologic agents are currently under development and clinical testing for atopic eczema.(18)

Using two large cohorts followed from birth for 4-5 decades that are representative of the general UK population, we sought to determine the proportion of individuals who develop symptoms of self-reported atopic eczema in childhood and adulthood, and examine factors associated with period of onset.
**Methods**

We performed a longitudinal cohort study using data from the 1958 and 1970 British Cohort Studies (BCS 1958 and BCS70), which are ongoing, multidisciplinary studies that include 17,196 and 17,415 babies born in Great Britain during one week in March 1958 and March 1970, respectively. There have been 8-9 subsequent waves of follow up in each cohort at approximately 5-10 year intervals (Figure 1). In the 1958 study, waves at ages 33, 46, and 55 did not include data on atopic eczema and thus were not included in the analysis. Additional information on response patterns in both cohorts has been reported elsewhere.

**Outcomes**

The primary outcome was parental or self-reported period prevalence of atopic eczema, based on a standardized question asking about “eczema” during or prior to the past year or since the last survey at each wave of follow up (Supplemental Table 1). In descriptive analyses, this measure coincided well with standardized clinical exams among children in the 1958 birth cohort, and a similar question has been shown to have high sensitivity and specificity for physician-diagnosed atopic eczema in US children and adults. We categorized individuals who reported atopic eczema into two groups: those whose first report of atopic eczema occurred in childhood (positive parental report during or prior to last year at age 5-7 and/or 10-11), and those with adult-onset atopic eczema (first report of atopic eczema at age 23+). For the primary analysis, we did not include atopic eczema data from age 16, because it is considered a transitional period between pediatric and adult care in the UK, and the 1958 cohort only asked about annual period prevalence (rather than period and lifetime prevalence at that age). In sensitivity analyses, data from age 16 were included.

**Covariates**

Additional covariates were chosen based on prior literature showing an association with atopic eczema. These included sex, ethnic group, history of any breastfeeding, region of residence in childhood, region of residence in adulthood (at age 42), childhood smoke exposure (either parent reporting current smoking during childhood surveys), smoking in adulthood (personal report of current smoking on any of the surveys in adulthood), household size (categorized into <=3 persons and 4+ persons), in utero smoke exposure (mother reported any smoking during pregnancy), birth weight, and the Registrar General’s designation of social class (a standard measure based on the father’s highest occupational status reported on any survey at ages 0-10/11 for childhood, and an individuals’ own occupation at ages 23-50 for adulthood). Personal history of asthma or allergic rhinitis/hay fever was based on questions repeated at multiple ages
(Supplemental Table 2). Data on parental history of asthma and hay fever was only available in the 1970 cohort, and was based on either parent’s report of either condition at age 5.

**Primary analysis**
In both cohorts, we estimated the cumulative lifetime prevalence and the age-specific period prevalence. We also calculated the proportion of individuals with childhood-onset versus adult-onset disease among those who reported active atopic eczema in adulthood. We used multivariable logistic regression to test for differences in demographic and risk factors between 1) childhood-onset and no atopic eczema, 2) adult-onset and no atopic eczema, and 3) childhood-onset versus adult-onset atopic eczema. After examining the regression results for consistency in each cohort separately, we conducted a meta-analysis of individual participant data, assuming fixed effects across studies and accounting for the clustering of participants within cohorts.(28)

**Subgroup analysis and biospecimen data**
For the subgroup of the 1958 cohort who had biospecimen data available, we repeated the regressions including variables for the presence of any filaggrin (FLG) null mutation; and a non-FLG genetic risk score, total IgE, and allergen-specific IgE modeled as 3-level categorical variables derived as tertiles.

At the age of 44-45 years, 5,974 individuals in the 1958 cohort were followed up with a biomedical examination and blood sampling,(29) from which a DNA collection was established as a nationally representative reference panel. In blood samples collected at this adult follow up, the total concentration of serum IgE antibodies and the presence of specific IgE to house dust mite, mixed grass pollen and cat fur were ascertained by Hytec enzyme immunoassay, with a detection threshold of 0.35 kU/L.(30) Four common null mutations of the FLG gene that have been associated with risk of atopic dermatitis in European populations(31, 32) were genotyped directly by LGC Genomics using KASP™ genotyping technology. FLG null status was defined as the presence of one or more risk variants of rs61816761 (R501X), rs150597413 (S3247X), rs558269137 (2282del4) or rs138726443 (R2447X , formerly rs386430951). An additional 29 variants outside the FLG region were selected for inclusion in a polygenic risk score, based on previously published associations with atopic dermatitis (please see supplement for additional description of methods and full list of references). A non-FLG genetic risk score was generated as the sum of imputed allele dosages for the risk-associated variant at each of these SNPs. Additional details are provided in the supplemental methods.

**Sensitivity analyses**
For the primary analysis, we did not include atopic eczema data from age 16, as described above. In a pre-planned sensitivity analysis, we tested the
impact of this decision on our results by including individuals who reported atopic eczema during the past year at age 16 with the childhood onset group. We also examined the potential for misclassification bias by restricting the sample to those who reported having seen a physician for their eczema in the past year, and had no history of self-reported psoriasis or contact dermatitis.

**Missing data**
We explored patterns of missing data throughout follow up and found that there was both intermittent missing survey data and attrition from the cohort. For the primary analysis, we included only individuals with at least one survey response in childhood and one survey response in adulthood (Figure 1). Additionally, to explore the impact of missing data, we performed multiple imputation in each cohort separately with iterative chained equations to impute missing exposure, outcome, and covariate data. Thirty imputed datasets were generated, and the average results from repeated analyses were compared to the complete case analysis. All statistical analyses were conducted using Stata, version 14 (StataCorp, Tx).

**Results**
At birth, 17,196 individuals were recruited to the 1970 cohort and 17,415 individuals were recruited into the 1958 cohort. There was intermittent missing data and attrition in both cohorts over time; 56-57% of the original birth sample responded to the last wave of follow up (Figure 1). Data on atopic eczema in both childhood and adulthood were available for 11,886 members of the 1970 cohort and 13,143 members of the 1958 cohort; demographic characteristics and missing covariate data are shown in Table 1 and Supplemental Table 3.

Consistent with international trends, atopic eczema was more common in the 1970 cohort: the cumulative lifetime prevalence of atopic eczema was 28% in the 1970 cohort and 18% in the 1958 cohort. Among those with atopic eczema at any time point, 40% and 43% reported disease for the first time in adulthood in the 1970 and 1958 cohorts, respectively. The period prevalence of atopic eczema ranged from 7-14% during any given period childhood and 5-12% during any given period in adulthood (Supplemental Table 1), and there was no clear trend across ages in either cohort (Figure 2). Among those who reported atopic eczema activity at each survey wave in adulthood, the majority (mean 62%) did not have a report of eczema during childhood (Figure 3).

The strength of association from multivariate regression models comparing individuals with childhood-onset atopic eczema and adult-onset atopic eczema to individuals without atopic eczema differed, as is evidenced by the results of the regression model directly comparing those with adult-onset to
childhood-onset disease (Table 2). We found that individuals with adult-onset atopic eczema were more likely to be women, from Northern geographic areas in the UK, from lower social class in childhood, and smoke during adulthood; but were less likely to have a history of asthma (Table 2).

In a sub-group analysis using data from 3,365 individuals in the 1958 cohort who were part of the biomedical follow up at age 44-45 and had atopic eczema, genetic, IgE, and covariate data available, we examined rates of known risk alleles for AD and both total IgE and allergen-specific IgE. We found that 21% of those with childhood-onset disease, 13% with adult-onset disease, and 10% of those without any history of atopic eczema had at least one FLG null mutation (Table 1). Both childhood-onset and adult-onset atopic eczema were associated with FLG null mutations, but the association was stronger for childhood-onset than adult-onset in multivariable analyses (OR 2.73, 95%CI 2.06-3.63, and OR 1.49, 95%CI 1.01-2.19, respectively; Table 3). A high non-FLG genetic risk score predicted childhood-onset atopic eczema, but there was little evidence for an association between the non-FLG genetic risk score and adult-onset disease (OR 1.81 95% CI 1.37-2.40, and OR 1.18, 95%CI 0.85-1.64, respectively; Table 3). Similarly, a high allergen-specific IgE predicted childhood-onset atopic eczema, but there was little evidence for an association between the allergen-specific IgE and adult-onset disease (OR 1.90, 95%CI 1.32-2.74, and 0.86, 0.54-1.36, respectively; Table 3).

Analyses after multiple imputation to address missing data showed similar results (Supplemental Table 4). In a sensitivity analysis using data from age 16, we found that an additional 260 individuals would be classified as having childhood-onset disease in the 1970 cohort and an additional 193 children in the 1958 cohort. The overall proportion with childhood-onset disease remained near 60% in both cohorts, and the results of the regression analyses did not change (Supplemental Table 5). Finally, when we excluded patients who had a history of contact dermatitis or psoriasis, or did not report seeing a physician in the past year for their atopic eczema (Supplemental Table 6), we again found similar results (Supplemental Table 7).

**Discussion**

Using two large population-based cohorts followed from birth into midlife, we found the period prevalence of self-reported atopic eczema was 5-14%. One of the defining characteristics of childhood atopic eczema is early age at onset; however, the majority of those reporting symptoms in adulthood did not have disease onset in childhood. When comparing those with childhood-onset and adult-onset atopic eczema, we found differences in demographic characteristics, atopic comorbidities, IgE profile in adulthood, and genetic risk factors. Our findings help to address the gap in knowledge about the
epidemiology of adult atopic eczema, and suggest that there may be different subtypes of adult disease that warrant additional characterization.

**Strengths and limitations**

Our study is unique in that there is prospective follow up of individuals residing in the UK from birth through mid-age. The data come from two large community-based cohorts broadly representative of the UK general population. Consistent with previous reports and international trends,(33-35) we found that the overall prevalence of atopic eczema increased between 1958 and 1970; but there did not appear to be a difference in trends across calendar year (Supplemental Figure 1). Two population-based mail surveys in the US and Italy also found high rates of adult-onset disease (54% and 60% of the population respectively,(7, 36)), but have been questioned because of the possibility for poor recall of childhood disease or migration to new climates.(16) These biases are unlikely to affect our estimates since individuals in our cohorts were born in the UK and followed with repeated assessments from birth through mid-life. We likely found a lower proportion of individuals with early-onset disease because our data included a longer duration of prospective follow-up than prior studies.(37) For example, an older study using data available through age 23 from the 1958 BCS concluded that of the 870 cases by the age of 16 years, 66% had age of onset by the age of 7 years.(38) By comparison, using the same initial data, now with extended follow-up through age 50, we found only 41% had onset of symptoms by age 7. Longitudinal studies of asthma have similarly found higher rates of late-onset and recurrent disease with longer periods of follow up.(39, 40)

A limitation of our study is that our outcome of atopic eczema was based on parental- or self-report and it is likely that some patients were misclassified. Misclassification could include other forms of eczema, including stasis dermatitis and irritant contact dermatitis in adults. Nearly all of the population-based epidemiologic literature on atopic eczema has relied on self-reported assessment of disease, and prior studies have shown that self-report performs reasonably well: in a multi-center US study with physician diagnosis as the gold standard, the positive predictive value of self-report was 0.87, 95% CI 0.78-0.96 in children and 0.76, 95% CI: 0.64-0.85 in adults. (25) Of note, it performed better for children than adults, and the study was conducted with dermatology clinic patients where the prevalence of atopic eczema was higher than the general population, meaning the estimates could be slightly inflated. Additional analyses to examine the potential for misclassification including restricting our sample to those who reported having seen a physician for their atopic eczema and never reported contact dermatitis and psoriasis were similar to the primary regression results (Supplemental Table 7). While these results do not rule out the potential for misclassification bias, they suggest that the magnitude of bias is likely to be small. Furthermore, as described in more detail below, our findings on
filaggrin mutations, IgE, and demographic factors are similar to smaller studies of clinical populations with physician-diagnosed atopic eczema. (15, 16, 41, 42)

An additional limitation of our study is that surveys were fielded at multi-year intervals and we cannot rule out the possibility that atopic eczema may be underreported. For example, some parents may not recall a history of early or mild atopic eczema when asked at age 5-7 of their child’s life; however, the recall is likely to be superior to surveys of adults asked about their own early childhood disease decades later. (43) Similarly, many of the adult surveys only asked about atopic eczema during the past year (as shown in supplemental table 1), and our results may underestimate adult-onset atopic eczema. Detailed phenotypic assessments of participants to detect atopic eczema at frequent intervals would be desirable, but they are impractical in large population-based cohorts followed for over 40 years.

Finally, as with any long-term study, the data are limited by attrition over time. Prior research has shown that in the 1970 cohort, there is a weak predictive effect of sex and socioeconomic status on response: men from lower social backgrounds with less educated parents are less likely to respond, which has previously been described in detail. (44) Because the cohort was not explicitly designed to study atopic disease, it is unlikely that attrition was differential by atopic eczema status. Nonetheless, to address missing data issues, we performed multiple imputation and found results that were consistent with the complete-case analysis.

Implications for research and clinical practice
Our results highlight the need for additional research to better characterize adult eczema and understand whether the pathophysiology differs by age of onset. Atopic eczema is known to have a multifactorial etiology, and we found genetic, immunologic, demographic, and risk factor differences between childhood onset and adult onset disease. Only a few other smaller studies have explicitly addressed age-associated differences in atopic eczema, and their findings are largely consistent with our results. Studies from dermatology clinic populations in Germany and the US also found that those with self-reported adult-onset disease were more likely to be female (42) and less likely to have a personal or family history of atopic disease (41, 42) elevated IgE levels; (41, 45) or filaggrin mutations, (46, 47) but did not find differences by smoking or socioeconomic status. (42) In contrast, a small case-control study from Taiwan found both current and ever smoking were strong independent risk factors for adult-onset disease, (48) and a recent meta-analysis found high rates of smoking in adults with AD overall, but did not differentiate by age of onset. (49)

Atopic eczema is considered to be a clinical diagnosis, and the most widely used diagnostic criteria (the Hanifin and Rajka criteria, the UK Working Party
criteria refinement of the Hanifin and Rajka criteria, and the American Academy of Dermatology criteria) all include early age at onset and history of atopy. Clinicians evaluating adults with a potential diagnosis of atopic eczema should recognize that the majority of patients may not have symptom onset in childhood. Moreover, while individuals with adult-onset disease have a higher probability of having a history of other atopic disease than individuals without atopic eczema, asthma is only present in about 1/3 and allergic rhinitis in about ½ of atopic eczema patients (Table 1). Diagnostic criteria were developed based on expert opinion among dermatologists whose clinical experience may not reflect the distribution of disease in the general population, and none have been validated in a population-based study of adults. Our data highlight the need to better understand what is adult “atopic” eczema and to refine diagnostic criteria for use in the general adult population. In the meantime, clinical trials of adult “atopic” eczema should describe the method by which physicians made the diagnosis (if any) and whether validated diagnostic criteria were used that would permit exploration or study heterogeneity and subgroup analyses in future meta-analyses.”

**Terminology**

We choose to use the term atopic eczema based on a call for consistency in the literature. There are regional variations in terminology; in the UK, the term ‘eczema’ is considered more precise than ‘dermatitis’; while in the US, the term ‘atopic dermatitis’ is usually preferred. In either case, use of the term ‘atopic’ has been debated because, even among children, not all disease is associated with elevated IgE levels or comorbid atopic conditions including asthma or rhinitis. Indeed, previous research has suggested that the majority of what is called atopic eczema is not atopic at a population-level. Our findings that adult-onset disease was associated with lower rates of IgE and asthma further call into question the use of the term ‘atopic’ in adult disease; nonetheless, we have continued to use this terminology for consistency and clarity. Future studies may uncover subtypes of adult-onset disease that require new terminology.

**Conclusion**

We found that self-reported adult-onset atopic eczema is common among two community-based British cohorts. Differences in genetic, demographic, and immunologic profiles between childhood-onset and adult-onset disease suggest there may be different subtypes of atopic eczema and emphasize the need for better characterization of adult-onset disease and validation of diagnostic tools in this population. These data are particularly timely because dozens of new treatments are under development and clinical testing for AD, and trial populations selected on the basis of early onset disease are unlikely to be representative of the general population of adults.
Acknowledgements: We are grateful to the participants in the British Longitudinal Cohort Studies, the Centre for Longitudinal Studies (CLS), UCL Institute of Education for the use of these data and to the UK Data Service for making them available. However, neither CLS nor the UK Data Service bear any responsibility for the analysis or interpretation of these data. We are also incredibly grateful for patient input from the National Eczema Association, Amanda Roberta, Nathan Jetter, John Lupiano, and Wendy Smith Begolka.
References


